Early use of insulin in type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 68, Issue SUPPL. 1, 2005, Pages

  Eldor, Roy ^a   Stern, Erwin ^b   Milicevic, Zvonko ^c   Raz, Itamar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c Lilly Area Medical Center Vienna   (Austria)

Author keywords

Diabetes mellitus type 2; Early insulin treatment; Glucotoxicity; Hypoglycemia

Indexed keywords

ANTIDIABETIC AGENT; ANTIOXIDANT; FATTY ACID; HUMAN INSULIN; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

CONFERENCE PAPER; DIETARY INTAKE; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE; MAXIMUM PERMISSIBLE DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS INSUFFICIENCY; PANCREAS ISLET BETA CELL; REMISSION; SIDE EFFECT; TREATMENT FAILURE; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; WEIGHT GAIN;

EID: 20444363109     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.03.004     Document Type: Conference Paper

References (56)

1. R.A. De Fronzo Pharmacologic therapy for type 2 diabetes mellitus Ann. Intern. Med. 131 1999 281 303
2. UK Prospective Diabetes Study Group Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 834 853
3. J.M. Cheolade, and A.D. Mooraolian A rational approach to drug therapy of type 2 diabetes mellitus Drugs 60 2000 95 113
4. J.B. Brown, G.A. Nichols, and A. Perry The burden of treatment failure in type 2 diabetes Diab. Care 27 2004 1535 1540
5. D.M. Nathan Insulin treatment of type 2 diabetes: the real deal Endocrinol. Rounds 1 1 2002 1 8 http://www.endocrinologyrounds.org
6. M. Yki-Jarvinen, L. Ryysy, and K. Nikkilu Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized controlled trial Ann. Intern. Med. 130 1988 389 396
7. E.J. Bastyr III, C.A. Stuart, and R.G. Brodous Therapy focused lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c-10E2 Study Group Diab. Care 23 2000 1236 1241
8. E. Ferrannini, A. Gastaldelli, Y. Miyazaki, M. Matsuda, A. Mari, and R.A. Defronzo Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis J. Clin. Endocrinol. Metab. 2004
9. T.A. Buchanan Pancreatic beta-cell loss and preservation in type 2 diabetes Clin. Ther. 25 Suppl. B 2003 32 46
10. R.P. Robertson, J. Harmon, P.O. Tran, Y. Tanaka, and H. Takahashi Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection Diabetes 52 2003 581 587
11. K. Grankvist, S.L. Marklund, and I.B. Taljedal CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse Biochem. J. 199 1981 393 398
12. M. Shimabukuro, Y.T. Zhou, M. Levi, and R.H. Unger Fatty acid-induced cell apoptosis: a link between obesity and diabetes PNAS 95 1998 2498 2502
13. Y. Lee, H. Hirose, Y.T. Zhou, V. Esser, J.D. McGarry, and R.H Unger Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM Diabetes 46 1997 408 413
14. R. Lupi, F. Dotta, L. Marselli, and S. Del Guerra Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated Diabetes 51 2002 1437 1442
15. P. Schrauwen, and M.K. Hesselink Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes Diabetes 53 2004 1412 1417
16. R.P. Robertson, J. Harmon, P.O. Tran, and V. Poitout Beta cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes Diabetes 53 Suppl. 1 2004 S119 S124
17. S. Krauss, C.Y. Zhang, L. Scorrano, and L.T. Dalgaard Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction J. Clin. Invest. 112 2003 1831 1842
18. M.Y. Donath, D.J. Gross, E. Cerasi, and N. Kaiser Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes Diabetes 48 1999 738 744
19. A.E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R.A. Rizza, and P.C. Butler Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes Diabetes 52 2003 102 110
20. A. Lorenzo, B. Razzaboni, G.C. Weir, and B.A. Yankner Pancreatic islet cell toxicity of amylin associated with type 2 diabetes mellitus Nature 368 1994 756 760
21. J. Janson, R.H. Ashley, D. Harrison, S. McIntyre, and P.C. Butler The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediatesized toxic amyloid particles Diabetes 48 1999 491 498
22. M. Biarné s, M. Montolio, V. Nacher, and M. Raurell Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia Diabetes 51 2002 66 72
23. K. Maedler, and Donath MY Beta-cells in type 2 diabetes: a loss of function and mass Horm. Res. 62 Suppl. 3 2004 67 73
24. B. Glaser, G. Leibovich, and R. Nesher Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes Acta Endocrinol. 118 1988 365 373
25. W.J. Andrews, B. Vasquez, and M. Nagulesparan Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal Diabetes 33 1984 634 642
26. W.T. Garvey, J.M. Olefsky, J. Griffin, R.F. Hamman, and O.G. Kolterman The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus Diabetes 34 1985 222 234
27. H. Ilkova, B. Glaser, and A. Tunckale Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment Diab. Care 20 1997 1353 1356
28. E.A. Ryan, S. Imes, and C. Wallace Short-term intensive insulin therapy in newly diagnosed type 2 diabetes Diab. Care 27 2004 1028
29. E.A. Sellers, and H.J. Dean Short-term insulin therapy in adolescents with type 2 diabetes mellitus J. Pediatr. Endocrinol. Metab. 17 2004 1561 1564
30. M. Alvarsson, G. Sundkvist, I. Lager, and M. Henricsson Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients Diab. Care 262 2003 231 237
31. R.C. Turner, C.A. Cull, V. Frighi, and R.R. Holman Glycemic control with diet, sulfonylureas, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) UK Prospective Diabetes Study (UKPD 5) Group JAMA 281 1995 2005 2012
32. J.A. Scarlett, R.S. Gray, and J. Griffin Insulin treatment reverses the insulin resistance of type 2 diabetes mellitus Diab. Care 5 1982 353 363
33. G. Romano, L. Patti, and F. Innelli Insulin and sulfonylurea therapy in NIDDM patients. Are the effects on lipoprotein metabolism different even with similar blood glucose control? Diabetes 46 1997 1601 1606
34. C.D. Miller, L.S. Phillips, and D.C. Ziemer Hypoglycemia in patients with type 2 diabetes mellitus Arch. Intern. Med. 161 2001 1653 1659
35. M. Shichiri, H. Kishikawa, Y. Ohdube, and N. Wake Long-term results of the Kumamoto Study in optimal diabetes control in type 2 diabetic patients Diab. Care 23 Suppl. 2 2000 21 29
36. H. Yki-Jarvinen, and A. Dressler Ziemen M - on behalf of the HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group Diab. Care 23 2000 1130 1136
37. J.H. Anderson, R.L. Brunele, and P. Decohanne Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with noninsulin-dependent diabetes mellitus. Multicenter Insulin Lyspro Study Group Arch. Intern. Med. 157 1997 1249 1255
38. UKPDS 34 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) UK Prospective Diabetes Study Lancet 352 1998 854 865
39. J.W. Campbell Metformin and the sulphonylureas; the comparative risk Horm. Metab. Res. Suppl. 15 1985 105 111
40. W. Berger, Caduff, M. Ponguel, and A. Rump The relatively frequent incidence of severe sulfonylurea-induced hypoglycaemia in the last 25 years in Switzerland. Results of 2 surveys in Switzerland in 1969 and 1981 Schweitz Med Wochenschr 116 1986 145 151
41. J. Krepinsky, A.J. Ingram, and C.M. Clase Prolonged sulfonylurea-induced hypoglycaemia in diabetic patients with end-stage renal disease Am. J. Kidney Dis. 35 2000 500 505
42. P.E. Cryer, J.N. Fisher, and M. Shamoon Hypoglycemia (Technical Review) Diab. Care 17 1994 734 755
43. S. Makimattila, K. Nikkila, and M. Yki-Jarvinen Cause of weight gain during insulin therapy with and without metformin in patients with type 2 diabetes mellitus Diabetologia 42 1999 406 412
44. R.R. Wolfe Effects of insulin on muscle tissue Curr. Opin. Clin. Nutr. Metab. Care 3 2000 67 71
45. S. Kersten Mechanisms of nutritional and hormonal regulation of lipogenesis EMBO Rep. 2 2001 282 286
46. R.A. DeFronzo The effect of insulin on renal sodium metabolism. A review with clinical implications Diabetologia 21 1981 165 171
47. S. Heller Weight gain during insulin therapy in patients with type 2 diabetes mellitus Diab. Res. Clin. Pract. 65 Suppl. 1 2004 23 27
48. DCCT (Diabetes Control and Complications Trial) Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial Diab. Care 24 2001 1711 1721
49. S.K. Garg, J.M. Paul, J.I. Karsten, L. Menditto, and P.A. Gottlieb Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes Diab. Technol. Ther. 6 2004 589 595
50. H. Yki-Jarvinen, L. Ryysy, and K. Nikkila Comparison of bedtime insulin regimens in patients with Type 2 diabetes mellitus: a randomized controlled trial Ann. Intern. Med. 130 1999 389 396
51. W.B. Chan, J.C. Chan, and C.C. Chow Glycemic control in type 2 diabetes: the impact of body weight, beta-cell function and patient education BJM 93 2000 183 190
52. A. Zambaniri, R.B. Newson, M. Maisey, and M.D. Feher Injection related anxiety in insulin-treated diabetes Diab. Res. Clin. Pract. 46 1998 239 246
53. F.D. Mollema, FJ. Sno-ek, R.J. Heine, and M.M. van Der Ploeg Phobia of self-injecting and self-testing in insulin treated diabetes patients: opportunities for screening Diab. Med. 18 2001 671 674
54. K. Malmberg, A. Norhoemmar, M. Weslel, and L. Ryden Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction; long term results DIGAMI (Diabetes and Insulin-Glucose infusion in Acute-Myocardial infarction) study Circulation 98 1999 2626 2632
55. F. Ovalle, and Bell DSH Effect of rosiglitazone versus insulin on the pancreatic cell function of subjects with type 2 diabetes Diab. Care 27 2004 2585 2589
56. J. Buteau, W. El-Assaad, and C.J. Rhodes Glucagon-like peptide-1 prevents beta cell glucolipotoxicity Diabetologia 47 2004 806 815